Ghana Pushes Pharmaceutical Self-Reliance to Strengthen Health Security
Ghana is seeking to strengthen its health security by expanding domestic pharmaceutical manufacturing and reducing reliance on imported medicines. According to ModernGhana, reporting on remarks by President John Dramani Mahama, the government has received a five-year plan to increase local production of medicines for domestic consumption while creating opportunities to export to neighbouring countries. Mahama said about 70% of medicines used in Ghana are currently imported, despite the country having the capacity to manufacture many medicines locally. The plan, presented by the National Vaccine Institute, the Ministry of Health, the Pharmaceutical Association of Ghana and other stakeholders, places local pharmaceutical production within a broader effort to strengthen the country’s capacity to meet essential healthcare needs.
The proposed expansion also connects pharmaceutical production with the government’s Free Primary Healthcare programme. Mahama said greater local manufacturing could help reduce medicine procurement costs and improve the availability of medicines for the programme. Building domestic capacity would also give Ghana greater control over an essential part of its health supply chain, while creating opportunities for investment, technology development and skilled employment. The initiative comes as Ghana continues to confront the vulnerability created by heavy dependence on imported pharmaceutical products, making the development of a stronger domestic manufacturing base an important component of longer-term health-sector resilience.
The pharmaceutical push therefore represents an opportunity to link health security with industrial development and economic self-reliance. A stronger domestic industry could reduce exposure to international supply disruptions and provide a foundation for Ghanaian manufacturers to serve markets beyond Ghana, particularly within West Africa. Achieving that objective will require sustained investment in production facilities, technology, skilled personnel, quality assurance and regulatory capacity, as well as predictable demand for locally manufactured medicines. The five-year plan is therefore best understood as a strategic framework rather than an achieved transformation. Its significance will depend on implementation and whether Ghana can convert its existing manufacturing capabilities into a competitive and sustainable pharmaceutical industry capable of supporting both national healthcare needs and wider regional markets.
